Ensysce Biosciences Inc (ENSC)vsMerck & Company Inc (MRK)
ENSC
Ensysce Biosciences Inc
$0.27
-2.56%
HEALTHCARE · Cap: $4.56M
MRK
Merck & Company Inc
$123.54
-1.22%
HEALTHCARE · Cap: $308.90B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 1396871% more annual revenue ($65.77B vs $4.71M). MRK leads profitability with a 13.6% profit margin vs -250.4%. MRK earns a higher WallStSmart Score of 50/100 (D+).
ENSC
Avoid31
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+59.5%
Fair Value
$1.01
Current Price
$0.27
$0.74 discount
Margin of Safety
-52.6%
Fair Value
$80.96
Current Price
$123.54
$42.58 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -1149.0% — below average capital efficiency
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ENSC
The strongest argument for ENSC centers on Debt/Equity.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : ENSC
The primary concerns for ENSC are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
ENSC profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
ENSC carries more volatility with a beta of 0.82 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 31/100). ENSC offers better value entry with a 59.5% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ensysce Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Ensysce Biosciences, Inc., a clinical-stage biotechnology company, is dedicated to the development of various prescription drugs. The company is headquartered in La Jolla, California.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?